Assembly Biosciences, Inc. (ASMB)

NASDAQ: ASMB · IEX Real-Time Price · USD
1.69
+0.03 (1.81%)
At close: Oct 4, 2022 4:00 PM
1.70
+0.01 (0.59%)
After-hours: Oct 4, 2022 5:51 PM EDT
1.81%
Market Cap 81.86M
Revenue (ttm) 6.25M
Net Income (ttm) -126.61M
Shares Out 48.44M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 158,670
Open 1.66
Previous Close 1.66
Day's Range 1.66 - 1.76
52-Week Range 1.32 - 3.43
Beta 0.72
Analysts Buy
Price Target 9.08 (+437.3%)
Earnings Date Nov 2, 2022

About ASMB

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutu... [Read more...]

Industry Biotechnology
IPO Date Dec 17, 2010
Employees 70
Stock Exchange NASDAQ
Ticker Symbol ASMB
Full Company Profile

Financial Performance

In 2021, ASMB's revenue was $6.25 million, a decrease of -92.09% compared to the previous year's $79.11 million. Losses were -$129.86 million, 108.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is 9.08, which is an increase of 437.28% from the latest price.

Price Target
$9.08
(437.28% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targe...

1 month ago - GlobeNewsWire

Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why

Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Best Momentum Stocks to Buy for August 4th

PI, INST and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2022.

Other symbols: INSTPI
2 months ago - Zacks Investment Research

New Strong Buy Stocks for August 4th

ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.

Other symbols: ARICBPIURI
2 months ago - Zacks Investment Research

Assembly Biosciences Announces Program Reprioritization and Organizational Update

- Discontinues clinical development of vebicorvir, Assembly Bio's first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies

2 months ago - GlobeNewsWire

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's Internatio...

SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targe...

3 months ago - GlobeNewsWire

7 Penny Stocks That Could Triple in 2022

Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks. The post 7 Penny Stocks That C...

Other symbols: ADNBOXDBRDSCMRXNNSOLO
3 months ago - InvestorPlace

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in ...

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targe...

3 months ago - GlobeNewsWire

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targe...

3 months ago - GlobeNewsWire

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Tr...

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targe...

3 months ago - GlobeNewsWire

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targe...

4 months ago - GlobeNewsWire

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics target...

4 months ago - GlobeNewsWire

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis ...

6 months ago - GlobeNewsWire

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

7 months ago - GlobeNewsWire

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

8 months ago - GlobeNewsWire

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

8 months ago - GlobeNewsWire

Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in...

9 months ago - Zacks Investment Research

Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibito...

Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation

10 months ago - GlobeNewsWire

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking HBV core inhibitor data will be highlighted in one oral and two poster presentations, in...

11 months ago - GlobeNewsWire

Assembly Bio Announces October Conference Participation

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

11 months ago - GlobeNewsWire

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates

1 year ago - GlobeNewsWire

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

1 year ago - GlobeNewsWire

Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B...

1 year ago - GlobeNewsWire